Eduardo San Martin Martinez

Dr. Eduardo San Martin Martinez

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 February 2021 in Journal of Biomedical Materials Research Part A
Verified
Journal Article
Closed access
PDF file
AHA. Hernández‐Rangel
A. Hernández‐Rangel
EMEduardo San Martin Martinez
Eduardo San Martin Martinez

18 March 2013 in Starch - Stärke
Verified
Journal Article
Closed access
PDF file
LOLesli Ortega‐Arroyo
Lesli Ortega‐Arroyo
EMEduardo San Martin Martinez
Eduardo San Martin Martinez
MAMiguel A. Aguilar‐Mendez
Miguel A. Aguilar‐Mendez
ACAlfredo Cruz‐Orea
Alfredo Cruz‐Orea
IHIsaias Hernandez‐Pérez
Isaias Hernandez‐Pérez
CGChrist Glorieux
Christ Glorieux

6 August 2019 in Journal of Materials Research
Verified
Journal Article
Closed access
PDF file
JVJosué Jiménez Vázquez
Josué Jiménez Vázquez
EMEduardo San Martin Martinez
Eduardo San Martin Martinez

4 January 2016 in Journal of Biomaterials Science, Polymer Edition
Verified
Journal Article
Closed access
RPRocio Guadalupe Casañas Pimentel
Rocio Guadalupe Casañas Pimentel
VBViviana Robles Botero
Viviana Robles Botero
EMEduardo San Martin Martinez
Eduardo San Martin Martinez
CGConsuelo Gómez García
Consuelo Gómez García
Juan HinestrozaJuan Hinestroza
Juan Hinestroza
Silver nanoparticles (AgNPs) induce diverse cell-death mechanisms, similar to those promoted by anticancer chemotherapeutics; however, they have not been tested in vivo because their action is not limited to cancer cells. Therefore, in vivo evaluations of their effectiveness should be developed with targeting systems. Breast cancer shows changes in the sugar expression patterns on cell surfaces, related to cancer progression and metastases; those changes have been identified previously by the specific binding of soybean agglutinin (SBA). Here is proposed the use of SBA to target the AgNP activity in breast cancer. For that, the present work reports the synthesis of AgNPs (3.89 ± 0.90 nm) through the polyol method, the generation of AgNP nanocarriers, and the bioconjugation protocol of the nanocarrier with SBA. The free AgNPs, the AgNP nanocarriers, and the SBA-bioconjugated AgNP nanocarriers were tested for cytotoxicity in breast cancerous (MDA-MB-231and MCF7) and non cancerous (MCF 10A) cells, using the MTT assay. AgNPs demonstrated cytotoxic activity in vitro, the non cancerous cells (MCF 10A) being more sensible than the cancerous cells (MDA-MB-231 and MCF7) showing LD50 values of 128, 205, and 319 μM Ag, respectively; the nanoencapsulation decreased the cytotoxic effect of AgNPs in non cancerous cells, maintaining or increasing the effect on the cancer-derived cells, whereas the SBA-bioconjugation allowed AgNP cytotoxic activity with a similar behavior to the nanocarriers. Future experiments need to be developed to evaluate the targeting effect of the SBA-bioconjugated AgNP nanocarriers to study their functionality in vivo.

27 April 2012 in Journal of Applied Polymer Science
Verified
Journal Article
Closed access
PDF file
HVH. Vieyra
H. Vieyra
MAM. A. Aguilar‐Méndez
M. A. Aguilar‐Méndez
EMEduardo San Martin Martinez
Eduardo San Martin Martinez

3 December 2010 in Starch - Stärke
Verified
Journal Article
Closed access
PDF file
HRHoracio Vieyra Ruiz
Horacio Vieyra Ruiz
EMEduardo San Martin Martinez
Eduardo San Martin Martinez
MMMiguel Ángel Aguilar Méndez
Miguel Ángel Aguilar Méndez